SPHRF (SPHRF) Stock Price & Analysis
SPHRF (SPHRF) fell 30.00% to USD 0.35 as of June 10, 2026 at 05:27 UTC, according to Nexqual real-time market data.
SPHRF last closed at USD 0.5; the session ranged USD 0.35–0.35 on volume of 6,475 shares. Market capitalization is $150.42M, with a 52-week range of USD 0.06–0.58 (OQX). Source: Nexqual, June 10, 2026 at 05:27 UTC.
Key Statistics (as of June 10, 2026 at 05:27 UTC)
| Price | USD 0.35 |
|---|---|
| Change | ▼ 30.00% (down) |
| Previous Close | USD 0.5 |
| Open | USD 0.35 |
| Day Range | USD 0.35 – 0.35 |
| 52-Week Range | USD 0.06 – 0.58 |
| Volume | 6,475 shares |
| Market Cap | $150.42M |
| Exchange | OQX |
Technical Analysis (SPHRF)
Nexqual's technical model rates SPHRF "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 05:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 81.06 (overbought) |
| vs SMA50 | Below (USD 0.42) |
| MACD | 0.03 (positive) |
Analyst Ratings (SPHRF)
Wall Street analysts rate SPHRF "None", per Nexqual as of June 10, 2026 at 05:27 UTC.
| Consensus Rating | None |
|---|
Earnings (SPHRF)
Source: Nexqual, June 10, 2026 at 05:27 UTC.
Financials & Fundamentals (SPHRF)
| Total Revenue | $14.58M |
|---|---|
| Revenue Growth (YoY) | +359.60% |
| Gross Margin | +29.59% |
| Operating Margin | +12.26% |
| Profit Margin | -22.16% |
| ROE | -14.47% |
| Debt / Equity | 3.68 |
| Current Ratio | 5.26 |
| Total Cash | $18.25M |
| Total Debt | $790,000 |
| Free Cash Flow | $-612,375 |
Source: Nexqual, June 10, 2026 at 05:27 UTC.
Financial Health Score (SPHRF)
Nexqual rates SPHRF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:27 UTC.
| Growth | Strong — Revenue +360% YoY (latest Q) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $18M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$852K |
| Efficiency | Critical — ROE -14%, ROA -7.2% |
Ownership (SPHRF)
| Insider Ownership | +27.62% |
|---|---|
| Institutional Ownership | +20.45% |
| Shares Outstanding | 420.93M |
| Float | 319.74M |
Source: Nexqual, June 10, 2026 at 05:27 UTC.
Leadership (SPHRF)
SPHRF is led by Cheryl Maley B.Sc. (age 57), CEO, MD & Director, per Nexqual as of June 10, 2026 at 05:27 UTC.
| CEO, MD & Director | Cheryl Maley B.Sc. (age 57) |
|---|---|
| CFO & Company Secretary | Justin Cahill |
| Director of People & Culture | Miranda Sowden |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPHRY | Starpharma Holdings Ltd. | USD 5.1 | ▼ 2.67% |
| PHGUF | Pharming Group NV | USD 1.18 | ▲ 0% |
| VBIZF | Viva Biotech Holdings | USD 0.15 | ▼ 6.25% |
| NNBP | NANOBAC PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| ACHFF | Arch Biopartners Inc. | USD 0.34 | ▼ 3.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:27 UTC. This page is informational and not investment advice.